Anteris Technologies (AVR) TD Cowen 45th Annual Healthcare Conference summary

Business overview and recent performance

• Focus on first-in-class medicines, with OJEMDA as a commercial product and DAY301 (PTK7-targeted ADC) in phase I trials.

• Achieved $57 million in revenue in the first eight months post-launch, with strong momentum into 2025.

• Over $500 million in cash, providing flexibility for pipeline execution and long-term growth.

• Continued enrollment in the FIREFLY-2 trial for tovorafenib and ribociclib in pediatric low-grade glioma.

OJEMDA launch and market penetration

• OJEMDA has been adopted by 100% of high-volume accounts and 75% of mid-tier accounts, with significant growth potential in lower-volume accounts.

• Physicians report positive experiences, especially with rapid patient response, encouraging further use.

• Barriers to adoption include waiting for appropriate patient opportunities and late adopters seeking peer experience.

• Broad uptake across patient age, tumor location, and genetic mutation, with most initial use in later-line patients.

Market dynamics and growth outlook

• The relapsed/refractory pediatric low-grade glioma market has 2,000–3,000 patients on therapy at any time, with 280 active patients on OJEMDA at year-end Q4.

• Growth expected to be steady, driven by new patient starts and continued therapy, with discontinuation rates consistent with clinical trials (median duration ~24 months).

• Frontline opportunity is significant, with 1,100 new patients annually; current use in frontline is limited but expected to grow with future trial readouts.